STAGE IV RENAL PELVIS CANCER AJCC V8
Clinical trials for STAGE IV RENAL PELVIS CANCER AJCC V8 explained in plain language.
Never miss a new study
Get alerted when new STAGE IV RENAL PELVIS CANCER AJCC V8 trials appear
Sign up with your email to follow new studies for STAGE IV RENAL PELVIS CANCER AJCC V8, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug combo targets tough bladder cancers
Disease control OngoingThis early-phase trial tests a combination of two drugs (erdafitinib and enfortumab vedotin) in about 24 people with advanced bladder cancer that has spread and has specific FGFR2/3 gene changes. The goal is to find the safest dose and see if the combo can shrink or stabilize the…
Matched conditions: STAGE IV RENAL PELVIS CANCER AJCC V8
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 17, 2026 01:43 UTC
-
New combo therapy shows promise for Tough-to-Treat bladder cancer
Disease control OngoingThis study tests whether adding the chemotherapy drug eribulin to the immunotherapy atezolizumab works better than atezolizumab alone for people with advanced bladder or urinary tract cancer who cannot take standard cisplatin chemotherapy. About 72 adults with cancer that has spr…
Matched conditions: STAGE IV RENAL PELVIS CANCER AJCC V8
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 17, 2026 01:41 UTC
-
New combo therapy aims to keep advanced bladder cancer at bay
Disease control OngoingThis phase III trial tests whether adding cabozantinib to avelumab (an immunotherapy) helps people with metastatic urothelial cancer live longer than avelumab alone. About 654 participants who have already completed initial chemotherapy will receive either the combination or avel…
Matched conditions: STAGE IV RENAL PELVIS CANCER AJCC V8
Phase: PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 15, 2026 18:57 UTC
-
New combo aims to tame immunotherapy side effects in advanced cancers
Disease control OngoingThis study tests whether adding tocilizumab to standard immunotherapy (ipilimumab and nivolumab) can reduce severe side effects in people with advanced melanoma, lung cancer, or bladder cancer. About 35 participants will receive the combination to see if it is safer and still eff…
Matched conditions: STAGE IV RENAL PELVIS CANCER AJCC V8
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 15, 2026 18:56 UTC
-
Could a common heart drug boost cancer immunotherapy?
Disease control OngoingThis study tests whether adding propranolol (a blood pressure drug) to standard immunotherapy can help people with advanced bladder cancer. It involves 6 adults whose cancer has spread or cannot be removed. The main goal is to check safety and see how the combination affects the …
Matched conditions: STAGE IV RENAL PELVIS CANCER AJCC V8
Phase: PHASE2 • Sponsor: Emory University • Aim: Disease control
Last updated Jun 11, 2026 12:09 UTC
-
Can a simple gene test predict who will beat bladder cancer?
Knowledge-focused OngoingThis study looks at whether certain genetic changes in tumors can help doctors know which patients with advanced bladder cancer will benefit from the immunotherapy drug nivolumab. Researchers are testing tumor samples for specific gene mutations and a protein called CXCL13. The g…
Matched conditions: STAGE IV RENAL PELVIS CANCER AJCC V8
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Knowledge-focused
Last updated Jun 15, 2026 19:02 UTC